111
Participants
Start Date
October 19, 2023
Primary Completion Date
July 9, 2025
Study Completion Date
July 9, 2025
CT-868
CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
CT-868 Pen Injector
The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
CT-868 Pen Injector, Placebo
The placebo pen injector is identical and contains the same ingredients except for CT-868.
MedStar Health Research Institute - Washington Hospital Center, Hyattsville
University of North Carolina at Chapel Hill, Chapel Hill
Lucas Research, Inc, Morehead City
University of North Carolina Health Sciences at MAHEC, Asheville
Atlanta Diabetes Associates, Atlanta
Advent Health, Orlando
Orlando Health Science Clinic, LLC, Orlando
Innovative Research Institute, Port Charlotte
Iowa Diabetes and Endocrinology Research Center, West Des Moines
Velocity Clinical Research - Dallas, Dallas
Research Institute of Dallas, Dallas
Diabetes & Glandular Disease Clinic, P.A., San Antonio
Consano Clinical Research, Shavano Park
Texas Valley Clinical Research, LLC, Weslaco
Texas Diabetes and Endocrinology, P.A, Austin
University of Colorado - Barbara Davis Center for Diabetes, Aurora
Denver Endocrinology Diabetes and Thyroid Center, Englewood
Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho, Idaho Falls
Headlands Research- AMCR, Escondido
John Muir Physician Network Clinical Research Center, Concord
Oregon Health and Science University, Portland
Rainier Clinical Research Center, Renton
Lead Sponsor
Carmot Therapeutics, Inc.
INDUSTRY